

Can't find Viloxazine (Qelbree) at your pharmacy? Explore alternative non-stimulant ADHD medications and learn what to discuss with your doctor about switching.
If you've been prescribed Viloxazine (Qelbree) for ADHD and can't find it at your pharmacy, you may be wondering what other options are available. While we always recommend trying to locate your prescribed medication first — tools like Medfinder can help you find Viloxazine in stock near you — it's also important to know what alternatives exist in case you need to switch.
In this guide, we'll explain what Viloxazine is, how it works, and walk you through the most common alternative medications your doctor might consider. Always consult with your healthcare provider before making any changes to your medication.
Viloxazine (brand name Qelbree) is a non-stimulant medication approved by the FDA to treat ADHD in patients aged 6 and older. It's manufactured by Supernus Pharmaceuticals and was first approved in April 2021.
Viloxazine belongs to a class of drugs called selective norepinephrine reuptake inhibitors (SNRIs). Unlike stimulant medications, it is not a controlled substance, which means it doesn't carry the same risk of abuse or dependence and is easier to prescribe and refill.
Viloxazine works by blocking the reuptake of norepinephrine in the brain, which increases the availability of this important neurotransmitter. Norepinephrine plays a key role in attention, focus, and executive function — the very things that are impaired in ADHD.
What makes Viloxazine unique compared to other non-stimulant ADHD medications is its additional effect on serotonin. It acts as a serotonin receptor modulator (specifically a 5-HT2B antagonist and 5-HT2C inverse agonist), which may contribute to its effectiveness and its potential mood-related benefits. This dual mechanism is different from Atomoxetine, which primarily affects norepinephrine alone.
If you can't find or tolerate Viloxazine, here are the most commonly considered alternatives. Each has its own mechanism of action, side effect profile, and practical considerations.
Atomoxetine is the most established non-stimulant ADHD medication and the closest alternative to Viloxazine. Like Viloxazine, it works by inhibiting norepinephrine reuptake, though it doesn't have the same serotonin-modulating effects.
Guanfacine extended-release is an alpha-2 adrenergic agonist approved for ADHD in children and adolescents aged 6–17. It works differently than Viloxazine — instead of blocking norepinephrine reuptake, it stimulates alpha-2A receptors in the prefrontal cortex, which helps improve attention and reduce impulsivity.
Clonidine extended-release is another alpha-2 adrenergic agonist similar to Guanfacine. It is FDA-approved for ADHD in children and adolescents aged 6–17 and is often used as an adjunct to stimulant medications.
If you were prescribed Viloxazine specifically because you wanted a non-stimulant option, stimulants may not be your first choice — but they remain the most effective class of ADHD medications for most patients. Common stimulant options include:
Stimulants work faster (often within the first dose) and have the strongest evidence base for ADHD treatment. However, they are controlled substances (Schedule II) and carry risks of dependence, cardiovascular effects, and appetite suppression. Discuss with your prescriber whether a stimulant might be appropriate for your situation.
The best alternative depends on your individual situation. Here are some factors to discuss with your healthcare provider:
Before switching to an alternative, make sure you've explored all options for finding Viloxazine. Use Medfinder to search pharmacies in your area — you may be surprised to find that an independent pharmacy or a location you hadn't considered has it in stock.
If you do need to switch, the most common non-stimulant alternatives to Viloxazine are:
For more information, explore our related guides:
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.